journal article·2022-07-06

pH/Thermal-Sensitive Nanoplatform Capable of On-Demand Specific Release to Potentiate Drug Delivery and Combinational Hyperthermia/Chemo/Chemodynamic Therapy

Nian Liu, Liang Wu, Wenbao Zuo, Qian Lin, Jinxue Liu, Quanyi Jin, Zhimei Xiao, Luping Chen, Yilin Zhao, Jun Zhou, Xuan Zhu

ACS Applied Materials & Interfaces· Volume 14· Issue 26
Publisher page

Abstract

Therapeutic platforms with spatiotemporal control were recently of considerable interest. However, the site-specific regulation of chemotherapeutics release remains an enormous challenge. Herein, a versatile nanoplatform capable of tumor-specific delivery and controlled drug release, coined as PDDFe, was constructed for elevating cancer theranostics. Iron-oxide nanoparticles (IONPs) and doxorubicin (Dox) were encapsulated in pH/thermal-sensitive micelles composed of poly(ethylene)glycol-poly(β-amino esters) and dipalmitoyl phosphatidylcholine to obtain tumor-targeted dual-responsive nanoplatforms. With remarkable magnetic targeting effects, PDDFe specifically accumulated at tumor locations. After internalization by cancer cells, the acidic environment and localized heat generated by hyperthermia therapy would spur PDDFe to become loose and collapse to liberate its payload. In addition to boosting the release, the increased temperature also resulted in direct tumor damage. Meanwhile, the released Dox and IONPs, respectively, stimulated chemotherapy and chemodynamic therapy to jointly destroy cancer, thus leading to a pronounced therapeutic effect. In vivo magnetic resonance/fluorescence/photoacoustic imaging experiments validated that the dual-sensitive nanoplatforms were able to accumulate at the tumor sites. Treatment with PDDFe followed by alternating magnetic field and laser irradiation could prime hyperthermia/chemo/chemodynamic therapy to effectively retard tumor growth. This work presents a nanoplatform with a site-specific controlled release characteristic, showing great promises in potentiating drug delivery and advancing combinational cancer therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Micro and Nano Robotics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, P. R. China

School of Medicine, Xiamen University, Xiamen 361102, P. R. China

Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, Shenzhen Zhongshan Urology Hospital, Shenzhen 518116, P. R. China

Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma (Xiamen University Affiliated ZhongShan Hospital), Xiamen 361004, P. R. China

Department of Pharmacy, South China Hospital of Shenzhen University, Shenzhen, Guangdong 518116, P. R. China

Funding

National Natural Science Foundation of China

References (43)

Show source-provided references
1. 10.1016/j.addr.2019.06.00710.1016/j.addr.2019.06.007 ↗
2. 10.1021/acs.jmedchem.1c0132810.1021/acs.jmedchem.1c01328 ↗
3. 10.1038/s41565-020-00793-010.1038/s41565-020-00793-0 ↗
4. 10.1007/s12274-020-3264-010.1007/s12274-020-3264-0 ↗
5. 10.1002/smll.20210444910.1002/smll.202104449 ↗
6. 10.1038/s41557-020-00624-810.1038/s41557-020-00624-8 ↗
7. 10.1021/acsnano.0c0890510.1021/acsnano.0c08905 ↗
8. 10.1002/adfm.20200375710.1002/adfm.202003757 ↗
9. 10.1002/advs.20200281610.1002/advs.202002816 ↗
10. 10.1021/acs.accounts.0c0033410.1021/acs.accounts.0c00334 ↗
11. 10.1039/c5cs00798d10.1039/c5cs00798d ↗
12. 10.1016/j.drudis.2017.11.00910.1016/j.drudis.2017.11.009 ↗
13. 10.1002/smtd.20210020410.1002/smtd.202100204 ↗
14. 10.1016/j.nantod.2020.10102210.1016/j.nantod.2020.101022 ↗
15. 10.1002/smll.20210434110.1002/smll.202104341 ↗
16. 10.1021/acsami.1c1385310.1021/acsami.1c13853 ↗
17. 10.1016/j.jconrel.2017.04.02810.1016/j.jconrel.2017.04.028 ↗
18. 10.1021/am403092m10.1021/am403092m ↗
19. 10.1016/j.mtchem.2021.10074010.1016/j.mtchem.2021.100740 ↗
20. 10.1002/adma.20200808910.1002/adma.202008089 ↗
21. 10.1021/acsami.0c1827310.1021/acsami.0c18273 ↗
22. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
23. 10.1016/j.jconrel.2021.03.02110.1016/j.jconrel.2021.03.021 ↗
24. 10.1039/c9nj00111e10.1039/c9nj00111e ↗
25. 10.1021/acs.nanolett.1c0218110.1021/acs.nanolett.1c02181 ↗
26. 10.1021/acsnano.5b0724910.1021/acsnano.5b07249 ↗
27. 10.1039/d1nr03335b10.1039/d1nr03335b ↗
28. 10.1016/j.jcis.2021.04.13110.1016/j.jcis.2021.04.131 ↗
29. 10.1016/j.jconrel.2021.05.02510.1016/j.jconrel.2021.05.025 ↗
30. 10.1002/adhm.20207006110.1002/adhm.202070061 ↗
31. 10.1002/anie.20200664910.1002/anie.202006649 ↗
32. 10.1039/d0bm01265c10.1039/d0bm01265c ↗
33. 10.1016/j.biomaterials.2021.12107110.1016/j.biomaterials.2021.121071 ↗
34. 10.1002/adma.20210039810.1002/adma.202100398 ↗
35. 10.1016/j.cej.2019.12379010.1016/j.cej.2019.123790 ↗
36. 10.1007/s13346-020-00729-010.1007/s13346-020-00729-0 ↗
37. 10.3389/fphar.2019.0076910.3389/fphar.2019.00769 ↗
38. 10.1021/acsami.1c1034110.1021/acsami.1c10341 ↗
39. 10.1016/j.biomaterials.2021.12071010.1016/j.biomaterials.2021.120710 ↗
40. 10.1021/acs.nanolett.0c0312710.1021/acs.nanolett.0c03127 ↗
41. 10.1007/s11095-008-9773-210.1007/s11095-008-9773-2 ↗
42. 10.1021/acsnano.0c0641510.1021/acsnano.0c06415 ↗
43. 10.1021/jacs.1c0747110.1021/jacs.1c07471 ↗